GO:0006004 fucose metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006004 (fucose metabolic process) describes the chemical reactions and pathways involving fucose, a 6-deoxygalactose sugar that exists as D-fucose and L-fucose.
• L-fucose is the predominant biologically relevant enantiomer in mammals, where it is activated to GDP-fucose and used for fucosylation of glycoproteins and glycolipids.
• Fucosylation regulates Notch signaling, selectin-mediated leukocyte adhesion, and host-microbe interactions, making fucose metabolism central to immunity and development.
• Defects in fucose metabolism and fucosylation cause congenital disorders of glycosylation (CDG) and are associated with cancer progression and immune evasion.
• Fucose analogs and fluorinated rhamnosides are powerful chemical tools to probe and inhibit cellular fucosylation.
• Engineered microbes can produce L-fucose, linking fucose metabolism to biotechnology and probiotic adaptation.
Description
Fucose metabolic process (GO:0006004) encompasses the chemical reactions and pathways involving fucose, or 6-deoxygalactose, which has two enantiomers, D-fucose and L-fucose. In mammals, L-fucose is the biologically dominant form and is incorporated into glycans as the terminal sugar of many cell-surface glycoproteins and glycolipids. The pathway includes de novo synthesis from GDP-mannose, salvage from dietary or lysosomal fucose, activation to GDP-fucose, and transfer onto acceptor substrates by fucosyltransferases. Fucosylation, the end product of fucose metabolism, is essential for Notch signaling, selectin-dependent leukocyte adhesion, and host-microbe recognition. Because fucose metabolism intersects with immunity, development, and cancer, it is a high-value target for functional genomics and therapeutic research.
fucose metabolic process At A Glance
| GO ID | GO:0006004 |
|---|---|
| GO term | fucose metabolic process |
| Ontology | biological_process |
| Synonym | fucose metabolism |
| Definition | The chemical reactions and pathways involving fucose, or 6-deoxygalactose, which has two enantiomers, D-fucose and L-fucose. |
| Major function | Synthesis, activation, transfer, and catabolism of fucose, especially L-fucose, for glycan fucosylation. |
| Key enzymes | GMDS, FCSK, FPGT, FUT family fucosyltransferases, FUCA1, FUCA2. |
| Key substrates | GDP-mannose, GDP-fucose, fucose-1-phosphate, L-fucose. |
| Disease links | Congenital disorders of glycosylation, cancer, immune disorders. |
What Is GO:0006004?
GO:0006004 is defined by QuickGO as the chemical reactions and pathways involving fucose, or 6-deoxygalactose, which has two enantiomers, D-fucose and L-fucose. In practice, this biological process covers the enzymatic steps that synthesize, interconvert, activate, and transfer fucose, as well as its catabolism and utilization in glycoconjugates.
Why Is fucose metabolic process Important in Cell Biology?
Fucose metabolic process is important because fucosylation is a major post-translational modification that controls cell-cell communication, immune recognition, and signal transduction. Disruptions in fucose metabolism alter Notch signaling and selectin ligand formation, which affects development and leukocyte trafficking. In cancer, aberrant fucosylation promotes tumor growth and immune evasion, making fucose pathway enzymes candidate therapeutic targets. Inborn errors in fucose metabolism cause CDG, and fucose analogs are used to dissect these pathways.
• Fucose is a terminal glycan modification that regulates Notch signaling and cell fate decisions.
• Fucosylated selectin ligands are required for leukocyte adhesion and immune surveillance.
• Defects in fucose metabolism cause congenital disorders of glycosylation with multisystem symptoms.
• Cancer cells often show altered fucosylation that supports proliferation and immune escape.
• Fucose analogs enable metabolic labeling and inhibition of fucosylation in live cells.
• Fluorinated rhamnosides inhibit cellular fucosylation, providing chemical probes.
• Probiotic bacteria use L-fucose operons to adapt to the gastrointestinal tract.
• Engineered E. coli can produce L-fucose for industrial and research applications.
• Fucose metabolism is a model for studying glycan biosynthesis and remodeling.
• Fucosylation influences host-microbe interactions and gut homeostasis.
What Happens During fucose metabolic process?
De novo synthesis of GDP-fucose from GDP-mannose
In simple terms: The cell builds the activated form of fucose from a common sugar nucleotide.
In the de novo pathway, GDP-mannose is converted to GDP-fucose through the sequential action of GMDS (GDP-mannose 4,6-dehydratase) and the epimerase-reductase FX (encoded by TSTA3/FX), producing GDP-fucose for fucosyltransferases. This pathway supplies the majority of GDP-fucose in many cell types and is essential for fucosylation of glycoproteins and glycolipids.
Salvage pathway and fucose activation
In simple terms: The cell recycles free fucose by phosphorylating it and converting it to GDP-fucose.
Free L-fucose from dietary sources or lysosomal degradation enters the salvage pathway, where FCSK (fucokinase) phosphorylates fucose to fucose-1-phosphate, and FPGT (fucose-1-phosphate guanylyltransferase) converts it to GDP-fucose. This salvage route allows efficient reuse of fucose and is particularly important in tissues with high fucose turnover.
Fucosyltransferase-mediated transfer
In simple terms: Enzymes attach fucose onto other molecules like proteins and lipids.
Fucosyltransferases (FUTs) transfer fucose from GDP-fucose to acceptor substrates such as N-glycans, O-glycans, and glycolipids, forming fucosylated glycoconjugates. Protein O-fucosylation, catalyzed by POFUT1 and POFUT2, is critical for Notch signaling and thrombospondin function. These modifications determine glycan recognition by lectins and antibodies.
Catabolism and turnover of fucose
In simple terms: The cell breaks down fucose to recycle it or use it for energy.
Fucose catabolism involves FUCA1 and FUCA2, alpha-L-fucosidases that remove fucose from glycans in lysosomes and extracellular spaces. Defects in FUCA1 cause fucosidosis, a lysosomal storage disorder, highlighting the importance of fucose turnover. Catabolic intermediates can feed into other metabolic pathways.
Fucose analogs and metabolic remodeling
In simple terms: Scientists use modified fucose molecules to track or block fucosylation.
Fucose analogs such as 6-azido-fucose and fluorinated rhamnosides are incorporated into glycans or inhibit fucosyltransferases, enabling metabolic labeling and functional studies of fucose metabolism. These tools reveal dynamic remodeling of glycan biosynthesis and are used to probe fucosylation in cancer and immunity.
Key Genes Involved in GO:0006004 fucose metabolic process
The following genes encode enzymes and transporters that carry out and regulate fucose metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GMDS | GDP-mannose 4,6-dehydratase in de novo GDP-fucose synthesis | Target for modulating fucosylation in cancer and development |
| TSTA3 (FX) | GDP-fucose synthase (epimerase-reductase) | Essential for GDP-fucose supply; knockout reduces fucosylation |
| FCSK | Fucokinase in salvage pathway | Regulates fucose salvage; mutations linked to CDG |
| FPGT | Fucose-1-phosphate guanylyltransferase | Salvage pathway enzyme; potential drug target |
| FUT1 | Alpha-1,2-fucosyltransferase (H antigen) | Blood group antigen synthesis; host-microbe interactions |
| FUT2 | Secretor-type alpha-1,2-fucosyltransferase | Gut microbiota and susceptibility to infection |
| FUT3 | Alpha-1,3/4-fucosyltransferase (Lewis antigens) | Cancer biomarker and adhesion |
| FUT4 | Alpha-1,3-fucosyltransferase (CD15/SSEA-1) | Notch signaling and leukocyte adhesion |
| FUT7 | Alpha-1,3-fucosyltransferase (selectin ligands) | Leukocyte trafficking and inflammation |
| FUT8 | Alpha-1,6-fucosyltransferase (core fucosylation) | Regulates receptor signaling and cancer progression |
| POFUT1 | Protein O-fucosyltransferase 1 | Notch signaling; knockout is embryonic lethal |
| POFUT2 | Protein O-fucosyltransferase 2 | Thrombospondin folding and secretion |
| FUCA1 | Lysosomal alpha-L-fucosidase | Fucosidosis; fucose catabolism |
| FUCA2 | Plasma alpha-L-fucosidase | Extracellular fucose turnover |
| SLC35C1 | GDP-fucose transporter | CDG-IIc; fucosylation defects |
| GFUS | GDP-fucose synthase (bifunctional) | Alternative GDP-fucose synthesis |
| FUK | Fucokinase (alternative name) | Salvage pathway regulation |
How Is fucose metabolic process Regulated?
Fucose metabolic process is regulated at multiple levels. The de novo pathway is controlled by the availability of GDP-mannose and the activity of GMDS and FX, while the salvage pathway is responsive to extracellular fucose levels and FCSK expression. Fucosyltransferase expression is tissue-specific and regulated by developmental and inflammatory signals, including Notch activation. In cancer, oncogenic signaling can upregulate FUT8 and other FUTs, increasing core fucosylation. Chemical inhibitors such as fluorinated rhamnosides can acutely block fucosylation, revealing dynamic regulation.
fucose metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCSK | CDG with developmental delay | Knockout HEK293 or patient iPSC-derived neurons |
| SLC35C1 | CDG-IIc (leukocyte adhesion deficiency II) | Knockout HL-60 cells for fucosylation |
| FUCA1 | Fucosidosis | FUCA1 knockout HeLa or mouse model |
| FUT8 | Cancer progression and immune evasion | FUT8 knockout cancer cell lines |
| FUT2 | Gut microbiota and infection susceptibility | FUT2 knockout intestinal organoids |
Congenital disorders of glycosylation (CDG)
Mutations in genes involved in fucose metabolism, such as FCSK and SLC35C1, cause CDG with developmental delay, immune deficiency, and neurological symptoms. These disorders highlight the essential role of fucose metabolism in human health.
Cancer and immune evasion
Altered fucosylation is a hallmark of many cancers; increased FUT8-mediated core fucosylation promotes tumor growth and immune evasion by modulating receptor signaling and immune checkpoint interactions. Targeting fucose metabolism is a promising anti-tumor strategy.
Fucosidosis and lysosomal storage
Deficiency of FUCA1 causes fucosidosis, a lysosomal storage disease characterized by accumulation of fucosylated glycans, leading to neurodegeneration and organomegaly. This demonstrates the importance of fucose catabolism.
Host-microbe interactions and infection
Fucosylated glycans serve as receptors for pathogens and nutrients for commensal bacteria; FUT2 secretor status influences susceptibility to infections and gut microbiome composition. Probiotic Lactobacillus rhamnosus GG uses an L-fucose operon to adapt to the gut.
From fucose metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GMDS reduce global fucosylation? | GMDS knockout HEK293 cells |
| How does FCSK mutation affect salvage pathway flux? | FCSK point-mutation knock-in cells |
| Can FUT8 overexpression enhance core fucosylation? | FUT8 overexpression in cancer cell lines |
| Where is POFUT1 localized during Notch signaling? | POFUT1 tagged knock-in (e.g., GFP) in mammalian cells |
| Does SLC35C1 deficiency impair leukocyte adhesion? | SLC35C1 knockout HL-60 cells |
| Can fucose analogs label newly synthesized glycans? | Metabolic labeling with azido-fucose in wild-type cells |
How to Study the fucose metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry glycomics | Fucosylated glycan structures | Profiling fucosylation in cancer cells |
| Lectin flow cytometry | Cell surface fucose levels | Screening CRISPR knockouts |
| Metabolic labeling with azido-fucose | Dynamic fucosylation | Imaging glycan turnover |
| FUT enzymatic assay | Fucosyltransferase activity | Testing inhibitors |
| RT-qPCR | Expression of fucose pathway genes | Validating knockout or overexpression |
| Western blot with fucose-specific lectin | Protein fucosylation | Assessing FUT8 targets |
| CRISPR library screening | Genes required for fucosylation | Identifying novel regulators |
| Bioinformatics pathway analysis | Gene enrichment in fucose metabolism | Interpreting omics data |
Glycan profiling by mass spectrometry
Mass spectrometry-based glycomics measures fucosylated N- and O-glycans, revealing changes in fucose metabolism. This method is used to quantify core fucosylation and Lewis antigen expression in cells and tissues.
Lectin-based detection and flow cytometry
Fucose-specific lectins such as UEA-I and AAL detect fucosylated glycans on cell surfaces by flow cytometry or blotting, enabling rapid assessment of fucosylation status. This is useful for screening CRISPR knockouts of fucose pathway genes.
Metabolic labeling with fucose analogs
Azide- or alkyne-tagged fucose analogs are incorporated into glycans and detected via click chemistry, allowing visualization of fucosylation dynamics in live cells. This technique is applied to study glycan remodeling and inhibitor efficacy.
Enzymatic assays for fucosyltransferases
In vitro assays using GDP-fucose and acceptor substrates measure FUT activity, and are used to characterize inhibitors such as fluorinated rhamnosides. These assays help dissect specific enzyme contributions to fucose metabolism.
How CRISPR Can Be Used to Study GO:0006004 fucose metabolic process
Knockout
CRISPR knockout of fucose pathway genes such as GMDS, FCSK, or FUT8 ablates specific steps, enabling researchers to determine their contribution to fucosylation and downstream phenotypes. Knockout cell models are used to study Notch signaling, immune adhesion, and cancer growth.
Point Mutation
Point mutations in genes like FCSK or SLC35C1 can mimic patient CDG variants, allowing structure-function studies and drug testing. CRISPR point-mutation knock-in models provide isogenic controls for disease mechanisms.
Knock-in
Knock-in of tagged alleles (e.g., GFP-POFUT1) enables live-cell imaging of enzyme localization and dynamics in fucose metabolism. Knock-in of reporter genes can also monitor fucosylation status.
Overexpression
Overexpression of FUT8 or other fucosyltransferases via CRISPR activation or cDNA integration increases fucosylation, modeling cancer-associated glycan changes. Overexpression models help test whether increased fucose metabolism drives malignant phenotypes.
How EDITGENE Supports fucose metabolic process Research
Researchers studying fucose metabolic process-related genes often need to determine whether a candidate gene is causally involved in glycan fucosylation, immune signaling, or disease progression. EDITGENE provides the full spectrum of CRISPR cell model engineering and screening services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for fucose metabolic process research.
Frequently Asked Questions About fucose metabolic process
What is fucose metabolic process?
Fucose metabolic process (GO:0006004) is the set of chemical reactions and pathways involving fucose, a 6-deoxygalactose sugar with D- and L-enantiomers, including its synthesis, activation, transfer, and catabolism.
What genes are involved in fucose metabolic process?
Key genes include GMDS, TSTA3, FCSK, FPGT, FUT1-11, POFUT1, POFUT2, FUCA1, FUCA2, and SLC35C1.
What is the function of fucose in glycans?
Fucose is a terminal glycan modification that regulates Notch signaling, selectin-mediated adhesion, and host-microbe interactions.
How is GDP-fucose synthesized?
GDP-fucose is synthesized de novo from GDP-mannose by GMDS and FX, or via the salvage pathway from free fucose by FCSK and FPGT.
What diseases are linked to fucose metabolism?
Defects cause congenital disorders of glycosylation and fucosidosis, and altered fucosylation is linked to cancer and immune disorders.
What are fucose analogs used for?
Fucose analogs such as azido-fucose are used for metabolic labeling and imaging of fucosylation, and fluorinated rhamnosides inhibit fucosylation.
How can I study fucose metabolism in the lab?
Common methods include mass spectrometry glycomics, lectin flow cytometry, metabolic labeling, and CRISPR knockout models.
What is the role of FUT8 in cancer?
FUT8-mediated core fucosylation promotes tumor growth and immune evasion, making it a therapeutic target.
What is fucosidosis?
Fucosidosis is a lysosomal storage disease caused by FUCA1 deficiency, leading to accumulation of fucosylated glycans.
Can bacteria metabolize fucose?
Yes, probiotic Lactobacillus rhamnosus GG uses an L-fucose operon to adapt to the gastrointestinal tract, and engineered E. coli can produce L-fucose.
Conclusion
Fucose metabolic process (GO:0006004) is a fundamental biological pathway that controls glycan fucosylation, with far-reaching roles in development, immunity, and disease. Understanding its enzymes and regulation offers opportunities for therapeutic intervention in cancer, CDG, and infectious disease. CRISPR-based models and chemical tools are accelerating discoveries in this field.
References
- 1. Holdener BC et al.. 2019. Protein O-fucosylation: structure and function.. Curr Opin Struct Biol 56:78-86 PMID: 30690220
- 2. Becerra JE et al.. 2015. An L-Fucose Operon in the Probiotic Lactobacillus rhamnosus GG Is Involved in Adaptation to Gastrointestinal Conditions.. Appl Environ Microbiol 81(11):3880-8 PMID: 25819967
- 3. Kizuka Y. 2022. Metabolic utilization and remodeling of glycan biosynthesis using fucose analogs.. Biochim Biophys Acta Gen Subj 1866(12):130243 PMID: 36087787
- 4. Schneider M et al.. 2017. Biological functions of fucose in mammals.. Glycobiology 27(7):601-618 PMID: 28430973
- 5. Liner AG et al.. 2026. Fucosylation in cancer and its role in anti-tumor immunity.. Eur J Cell Biol 105(3):151547 PMID: 42314439
- 6. Pijnenborg JFA et al.. 2021. Fluorinated rhamnosides inhibit cellular fucosylation.. Nat Commun 12(1):7024 PMID: 34857733
- 7. Brasil S et al.. 2018. CDG Therapies: From Bench to Bedside.. Int J Mol Sci 19(5) PMID: 29702557
- 8. Liu JJ et al.. 2019. L-Fucose production by engineered Escherichia coli.. Biotechnol Bioeng 116(4):904-911 PMID: 30597526
